SHR-1701 (Retlirafusp alfa) is a bifunctional fusion protein targeting PD-L1 and TGF-β for cancer research.
SHR-1701 (10 μg/mL) can inhibit TGF-β signaling pathway, activate PI3K/Akt/Erk signaling pathway, rescue lymphocytes and restore the anti-tumor function of peripheral blood CD8+ T cells in patients with lung cancer[1].
References:
[1]. Bo Cheng, et al. Anti-PD-L1/TGF-βR fusion protein (SHR-1701) overcomes disrupted lymphocyte recovery-induced resistance to PD-1/PD-L1 inhibitors in lung cancer. Cancer Commun (Lond). 2022 Jan;42(1):17-36.